MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GDRX stock logo

GDRX

GoodRx Holdings, Inc.

$2.65
0.02
 (0.76%)
Exchange:  NASDAQ
Market Cap:  918.568M
Shares Outstanding:  385.385M
Delayed data
Calculate GDRX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Wendy Barnes
Full Time Employees:  738
Address: 
2701 Olympic Boulevard
Santa Monica
CA
90404
US
Website:  https://www.goodrx.com
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/08 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue750,265792,324796,853
Gross Profit683,340744,109739,256
EBITDA108,824153,920184,361
Operating Income-27,00765,84687,492
Net Income-8,86816,39030,439

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,588,8001,388,0671,404,058
Total Liabilities826,842663,409787,796
Total Stockholders Equity761,958724,658616,262
Total Debt711,070543,38759,542
Cash and Cash Equivalents672,296448,346261,820

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow138,292163167,904
Capital Expenditure-55,7660-3,521
Free Cash Flow82,526163164,383
Net Income-8,86816,39030,439
Net Change in Cash-84,869-223,9500

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)986,851.536Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,025,097.505Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,007,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)402,060.187Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)417,642.249Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)410,269.016Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)0Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)0Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)622,314.017Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)646,432.136Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)635,019.750Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
792.324M  ?P/S
 (TTM)
: 
1.17
?Net Income
 (TTM)
: 
16.39M  ?P/E
 (TTM)
: 
43.9
?Enterprise Value
 (TTM)
: 
1.224B  ?EV/FCF
 (TTM)
: 
9.3
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.03  ?ROIC
 (TTM)
: 
0.03
?Net Debt
 (TTM)
: 
95.041M  ?Debt/Equity
 (TTM)
: 
0.87
?P/B
 (TTM)
: 
1.45  ?Current Ratio
 (TTM)
: 
1.47

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
8.55Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates GDRX intrinsic value between $0.01 – $4.34 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about GDRX valuation

Is GoodRx Holdings, Inc. (GDRX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for GoodRx Holdings, Inc. (GDRX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GDRX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GDRX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GDRX’s P/E ratio?

You can see GDRX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GDRX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GDRX a good long-term investment?

Whether GDRX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

GDRX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.76
MARKETSnap

Trading Metrics:

Open: 2.67   Previous Close: 2.63
Day Low: 2.57   Day High: 2.78
Year Low: 1.77   Year High: 5.81
Price Avg 50: 2.46   Price Avg 200: 2.94
Volume: 1.557M   Average Volume: 1.736M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
08-05-2026 00:51
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Big Pharma Runs Its Checkout Counter Through GoodRx
07-05-2026 13:08
Big Pharma Runs Its Checkout Counter Through GoodRx
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
06-05-2026 20:31
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
17-04-2026 16:05
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
15-04-2026 13:25
GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price
15-04-2026 09:00
GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read